title: Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes.
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Fukuda
authors.forename: Tomoko
authors.initials: T
authors.lastname: Tanabe
authors.forename: Masako
authors.initials: M
authors.lastname: Ohno
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Tougou
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Fujio
authors.forename: Junichi
authors.initials: J
authors.lastname: Azuma
authors.forename: Isamu
authors.initials: I
authors.lastname: Yamamoto
authors.forename: Akira
authors.initials: A
authors.lastname: Takeda
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D004305:Dose-Response Relationship, Drug; D005838:Genotype; D006470:Hemorrhage / Q000188:drug therapy / Q000235:genetics; D006720:Homozygote; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics*; D013237:Stereoisomerism; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry
chemical_list: D000925:Anticoagulants; D014859:Warfarin; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases